We rank companies based on fund manager, research analyst and news sentiment
APM stock icon

Aptorum Group


About: Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.

Employees: 19

Funds holding %
of 6,474 funds
Analysts bullish %
News positive %

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

1.04% less ownership

Funds ownership: 2.53% [Q3] → 1.49% (-1.04%) [Q4]

18% less capital invested

Capital invested by funds: $126K [Q3] → $104K (-$22.1K) [Q4]

40% less funds holding

Funds holding: 5 [Q3] → 3 (-2) [Q4]

67% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 3

Research analyst outlook

We haven’t received any recent analyst ratings for APM.

Financial journalist opinion